

## Prior Authorization Updates November 2021

Cook Children's Health Plan has updated the following procedure codes (s) with an effective date of 12/1/2021. Providers may contact [CCHPPriorAuthorizations@cookchildrens.org](mailto:CCHPPriorAuthorizations@cookchildrens.org) for with questions specific to authorizations. For additional questions please contact Cook Children's Health Plan Provider Support Services at 888-243-3312 or email [CCHPPProviderRelations@cookchildrens.org](mailto:CCHPPProviderRelations@cookchildrens.org).

Procedure Code	Code Description	Added, Terminated, Revised	Effective date of change	STAR	CHIP	STAR Kids
L5622	Addition to lower extremity, test socket, knee disarticulation	Terminated	12/1/2021	X	X	X
L5814	Addition, endoskeletal knee-shin system, polycentric, hydraulic swing phase control, mechanical stance phase lock	Terminated	12/1/2021	X	X	X
C9081	Idecabtagene vicleucel, up to 460 million autologous anti-BCMA CAR-positive viable T cells, including leukapheresis and dose preparation procedures, per therapeutic dose	Added	10/1/2021	X	X	X
C9082	Injection, dostarlimab-gxly, 100 mg	Added	10/1/2021	X	X	X
C9083	Injection, amivantamab-vmjw, 10 mg	Added	10/1/2021	X	X	X
C9084	Injection, loncastuximab tesirine-lpyl, 0.1 mg	Added	10/1/2021	X	X	X
J0699	Injection, cefiderocol, 10 mg	Added	10/1/2021	X	X	X
J9247	Injection, melphalan flufenamide, 1 mg	Added	10/1/2021	X	X	X
J9318	Injection, romidepsin, nonlyophilized, 0.1 mg	Added	10/1/2021	X	X	X
J9319	Injection, romidepsin, lyophilized, 0.1 mg	Added	10/1/2021	X	X	X
M0240	Intravenous infusion or subcutaneous injection, casirivimab and imdevimab, includes infusion or injection and post administration monitoring, subsequent repeat doses	Added	7/30/2021	X	X	X

M0241	Intravenous infusion or subcutaneous injection, casirivimab and imdevimab, includes infusion or injection, and post administration monitoring in the home or residence. This includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency, subsequent repeat dose	Added	7/30/2021	X	X	X
M0244	Intravenous infusion or subcutaneous injection, casirivimab and imdevimab, includes infusion or injection and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the COVID-19 public health emergency	Added	5/6/2021	X	X	X
M0246	Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the COVID-19 public health emergency	Added	5/6/2021	X	X	X
M0248	Intravenous infusion, sotrovimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the COVID-19 public health emergency	Added	5/26/2021	X	X	X
Q2054	Lisocabtagene maraleucel, up to 110 million autologous anti-CD19 CAR-positive viable T cells, including leukapheresis and dose preparation procedures, per therapeutic dose	Added	10/1/2021	X	X	X
C9077	Injection, cabotegravir and rilpivirine, 2 mg/3 mg	Terminated	9/30/2021	X	X	X
J0741	Injection, cabotegravir and rilpivirine, 2 mg/3 mg	Added	10/1/2021	X	X	X
C9079	Injection, evinacumab-dgnb, 5 mg	Terminated	9/30/2021	X	X	X
J1305	Injection, evinacumab-dgnb, 5 mg	Added	10/1/2021	X	X	X
C9075	Injection, casimersen, 10 mg	Terminated	9/30/2021	X	X	X

J1448	Injection, trilaciclib, 1 mg	Added	10/1/2021	X	X	X
J1426	Camiersen (Amondys 45)	Added	11/1/2021	X	X	X
J1427	Viltolarsen (Viltepsa)	Added	11/1/2021	X	X	X
Q2053	Brexucabtagene Autoleucel (Tecartus)	Revised	11/1/2021	X	X	X
J1442	Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram	Revised	11/1/2021	X	X	X
J1447	Injection, tbo-filgrastim, 1 microgram	Revised	11/1/2021	X	X	X
Q5101	Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram	Revised	11/1/2021	X	X	X
J2505	Injection, pegfilgrastim, 6 mg	Revised	11/1/2021	X	X	X
Q5108	Pegfilgrastim (FullInjection, pegfilgrastim-jmdb, biosimilar, (fulphila), 0.5 mg	Revised	11/1/2021	X	X	X
Q5110	Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram	Revised	11/1/2021	X	X	X
Q5120	Injection, pegfilgrastim-bmez, biosimilar, (ziextenzo), 0.5 mg	Revised	11/1/2021	X	X	X
Q5122	Injection, pegfilgrastim-apgf, biosimilar, (nyvepria), 0.5 mg	Revised	11/1/2021	X	X	X